Ipreo Debtdomain Supports "Leveraged Finance Fights Melanoma"

NEW YORK, May 13, 2013 /PRNewswire/ -- Ipreo, a leading global provider of workflow solutions and market intelligence to capital markets and corporate professionals, announced its support of "Leveraged Finance Fights Melanoma" (LFFM), an event to benefit the Melanoma Research Alliance's (MRA) global research and awareness program by leading a campaign to promote individual skin check-ups by physicians.

Regular skin checks can save lives by detecting melanoma and other skin cancers at their earliest stages when they are most likely to be cured. To help generate awareness, Ipreo has created the "Ipreo Debtdomain Skin Check Pledge." For each person who pledges to have completed a skin cancer screening in the last six months or to make an appointment for a skin check within three months, a group comprised of Ipreo, the private equity firm of KKR, and select LFFM donors will donate $100 to benefit the MRA, up to a $250,000 combined donation. 

MRA is the largest private funder of melanoma research. LFFM is an annual event that brings together the biggest names in Leveraged Finance to raise funds to benefit the MRA in its fight against melanoma.

"We are proud to be supporting such a worthy cause," said David Levy, EVP & Managing Director, Debtdomain Syndicated Loans at Ipreo. "Melanoma is a terrible disease, but also very curable if caught early. We're pleased to be joining forces with other members of the Leveraged Finance community to support the MRA and encourage as many people as possible to get screened."

"The 'Skin Check Campaign' is a very tangible and generous program to prompt people to do something important for themselves and their families," said Wendy Selig, MRA CEO.  "It is a wonderful opportunity to save lives. Ipreo is setting an important example of corporate leadership, as have an increasing number of MRA allies who similarly are now engaged with us in this crucial effort to support research and promote greater awareness about deadly skin cancer."

To take the "Ipreo Debtdomain Skin Check Pledge" and access more info about LFFM and the MRA, visit www.debtdomain.com/lffm.

About Ipreo Debtdomain

Ipreo is a global leader in providing market intelligence, data, and technology solutions to all participants in the global capital markets, including sell-side banks, publicly traded companies, and buy-side institutions. By combining state-of-the-art new issuance systems with the premier global financial and investor data, Ipreo enables our capital markets clients to execute deals more efficiently, saving time and resources. Ipreo is the only financial services provider to offer solutions to all participants across all asset classes for the Loan Syndication, Fixed Income, Municipal and Equity markets. Ipreo is a KKR portfolio company with more than 650 employees supporting clients in every major financial hub around the world.

Debtdomain is a web-based system for managing the loan syndication process from pitch to agency. The solution covers deal setup, pipeline reporting, sole and joint bookrunning, and secure document distribution. Debtdomain also offers an investor CRM tool powered by a database of over 200,000 contacts, and integrated with bookrunning and deal sites. Debtdomain is used by over 150 leading loan market arrangers and agents.

About the Melanoma Research Alliance

MRA is a public charity formed in 2007 under the auspices of the Milken Institute, with the generous founding support of Debra and Leon Black. MRA is poised to build on recent momentum in the field, accelerating the pace of scientific discovery and translation in order to eliminate suffering and death due to melanoma.  MRA's ability to fund wide-ranging research in melanoma is amplified by unique multi-faceted collaborations and partnerships with individuals, private foundations and corporations. For more information, please visit www.curemelanoma.org.

SOURCE Ipreo

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED